| Sorafenib Tosylate |
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate) |
| (CAS 4750207-59-1) |
 |
| Description： |
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar),[1] is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma). Sorafenib (a bi-aryl urea[2]) is a small molecular inhibitor of several Tyrosine protein kinases (VEGFR and PDGFR) and Raf kinases (more avidly C-Raf than B-Raf). (Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous. These pathways include Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 and 3 kinases and c Kit the receptor for Stem cell factor. ) Sorafenib is/was unique in targeting the Raf/Mek/Erk pathway (MAP Kinase pathway). Sorafenib inhibits some intracellular serine/threonine kinases (e.g. C-Raf, wild-type B-Raf and mutant B-Raf).
|
| Product No. |
KT20011 |
| Product Name |
Sorafenib Tosylate |
| Synonyms |
BAY 43-9006;Nexavar(R);UNII-5T62Q3B36J |
| Formal Name |
1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea mono(4-methylbenzenesulfonate) |
| CAS Number |
4750207-59-1 |
| Molecular Formula |
C21H16ClF3N4O3 |
| Formula Weight |
637.03 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20℃ |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
1-Naphtyl PP1
1-NM-PP1
Ponatinib
Bosutinib
Erlotinib
BIBW 2992
Mubritinib
Pelitinb
|
|
